- Price
- $143.59
- Day
- +0.10%
- Mkt Cap
- $16.02B
- 52W Range
- $81.22 – $149.52
- Volume
- 2.06M
- Beta
- 1.09
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Revvity (NYSE: RVTY - Get Free Report) and Cytek Biosciences (NASDAQ: CTKB - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership. Analyst Recommendations This is a summary of current recommendations
Read full article
Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read full article
Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript
Read full article
Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read full article
Amundi lowered its position in Revvity Inc. (NYSE: RVTY) by 7.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 159,232 shares of the company's stock after selling 12,288 shares during the quarter. Amundi owned about 0.14% of Revvity worth $17,716,000
Read full article
California State Teachers Retirement System increased its holdings in Revvity Inc. (NYSE: RVTY) by 10,607.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,328,063 shares of the company's stock after buying an additional 14,194,254 shares during the quarter. California
Read full article
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
Read full article
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read full article
Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
Read full article
WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including.
Read full article
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Read full article
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read full article